We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+4.2%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$372M
AUM Growth
+$48.1M
Cap. Flow
+$80.2M
Cap. Flow %
21.56%
Top 10 Hldgs %
69.34%
Holding
99
New
19
Increased
13
Reduced
16
Closed
23

Top Buys

Rank Stock Value
1
AKTS
Aktis Oncology
AKTS
+$61.4M
2
MPLT
MapLight Therapeutics
MPLT
+$12.1M
3
ENGN icon
enGene Therapeutics
ENGN
+$9.4M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$8.7M
5
EYPT icon
EyePoint Inc
EYPT
+$7.78M

Top Sells

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$8.95M
2
PCOR icon
Procore
PCOR
+$6.86M
3
ROIV icon
Roivant Sciences
ROIV
+$5.71M
4
CGEM icon
Cullinan Oncology
CGEM
+$5.67M
5
CNTX icon
Context Therapeutics
CNTX
+$5.47M

Sector Composition

Rank Sector Weight
1 Healthcare 76.1%
2 Financials 13.79%
3 Consumer Discretionary 4.78%
4 Technology 2.41%
5 Real Estate 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
26
Pliant Therapeutics
PLRX
$68.1M
$3.74M 1.01%
2,969,199
– –
STWD icon
27
Starwood Property Trust
STWD
$6.18B
$2.73M 0.73%
+158,545
New +$2.85M
ADCT icon
28
ADC Therapeutics
ADCT
$154M
$2.59M 0.7%
733,568
– –
EVMN
29
Evommune Inc
EVMN
$430M
$2.3M 0.62%
+100,000
New +$2.26M
DELL icon
30
Dell
DELL
$276B
$2.28M 0.61%
13,899
-39,949
-74% -$5.32M
LRMR icon
31
CALL
Larimar Therapeutics
LRMR
$420M
$1.91M 0.51%
+975,700
New +$3.9M
ORIC icon
32
Oric Pharmaceuticals
ORIC
$1.27B
$1.9M 0.51%
150,000
-365,000
-71% -$4.14M
SGMT icon
33
Sagimet Biosciences
SGMT
$459M
$1.74M 0.47%
333,877
-910,000
-73% -$5.07M
WW
34
WW International
WW
$134M
$1.31M 0.35%
+95,634
New +$2.14M
ENGNW icon
35
enGene Therapeutics Warrants
ENGNW
$3.75M
$1.29M 0.35%
511,177
+475,077
+1,316% +$1.41M
EPD icon
36
Enterprise Products Partners
EPD
$82.5B
$1.18M 0.32%
31,290
– –
FLD
37
Fold Holdings
FLD
$22.9M
$1.13M 0.3%
856,632
– –
OPTXW icon
38
Syntec Optics Holdings Warrant
OPTXW
$14.8M
$867K 0.23%
803,132
– –
MRKR icon
39
Marker Therapeutics
MRKR
$20.8M
$721K 0.19%
554,250
– –
MLYS icon
40
CALL
Mineralys Therapeutics
MLYS
$2.46B
$590K 0.16%
+200,000
New +$5.87M
NIOBW
41
NioCorp Developments Ltd Warrant
NIOBW
$55.2M
$525K 0.14%
320,100
-556,048
-63% -$1.24M
CMPX icon
42
CALL
Compass Therapeutics
CMPX
$391M
$500K 0.13%
+400,000
New +$2.31M
BNAIW
43
Brand Engagement Network Warrant
BNAIW
$2.26M
$417K 0.11%
1,666,808
-1,059,468
-39% -$255K
CAH icon
44
Cardinal Health
CAH
$53.4B
$363K 0.1%
1,718
– –
RZLVW
45
Rezolve AI Warrants
RZLVW
$5.4M
$202K 0.05%
235,121
-54,188
-19% -$57.8K
PIPR icon
46
Piper Sandler
PIPR
$5.2B
$186K 0.05%
2,428
– –
AMOD
47
Alpha Modus Holdings
AMOD
$18M
$146K 0.04%
9,852
– –
CMPS
48
CALL
Compass Pathways
CMPS
$1.55B
$132K 0.04%
+900,000
New +$6.05M
ET icon
49
Energy Transfer Partners
ET
$68.9B
$103K 0.03%
+5,326
New +$97.5K
DAIC
50
CID HoldCo Inc
DAIC
$1.56M
$94.8K 0.03%
22,294
– –
1
2
3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q1 2026 Portfolio in Review

As of Q1 2026, Blue Owl Capital Holdings held 99 positions worth $372M, up 15% from $324M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Blue Owl Capital Holdings deployed $80.2M of net new capital in Q1 2026, opening 19 new positions and adding to 13 existing holdings. Its largest new stake was Aktis Oncology: 3,161,348 shares worth $56.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 64% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $5.67M trimmed.

  • Blue Owl Capital Holdings's largest Q1 2026 buy was Aktis Oncology: 3,161,348 shares worth $56.6M.
  • Blue Owl Capital Holdings added most to MapLight Therapeutics in Q1 2026, an estimated $12.1M increase.
  • Blue Owl Capital Holdings's biggest Q1 2026 reduction was Cullinan Oncology, cutting an estimated $5.67M.
  • Blue Owl Capital Holdings fully exited Repare Therapeutics in Q1 2026, selling an estimated $8.95M.
  • Blue Owl Capital Holdings's ten largest holdings make up 69% of its $372M portfolio in Q1 2026.
  • Blue Owl Capital Holdings opened 19 new positions and closed 23 in Q1 2026.
  • Blue Owl Capital Holdings's portfolio value rose 15% quarter-over-quarter to $372M.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.